<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685252</url>
  </required_header>
  <id_info>
    <org_study_id>19.16.NRC</org_study_id>
    <nct_id>NCT04685252</nct_id>
  </id_info>
  <brief_title>Investigating a Probiotic on Mothers' Mood and Stress</brief_title>
  <acronym>Promote</acronym>
  <official_title>Investigating a Probiotic on Mothers' Mood and Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blind, 3 parallel-arm study in pregnant&#xD;
      women aged 21 years old and above. The study aims to assess changes in perinatal mood and&#xD;
      stress when administering a probiotic starting from either the 3rd trimester (i.e 28-32 weeks&#xD;
      of gestational age) or immediately after birth, until 12 weeks post-partum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, limited evidence is available for nutritional interventions in the role of&#xD;
      modulation of perinatal mood and stress, even less so for probiotics. The probiotic strain&#xD;
      Bifidobacterium longum (BL) NCC3001 has previously been shown to normalize anxiety-like&#xD;
      behavior in preclinical models and to reduce feelings of low mood and emotional reaction to&#xD;
      fearful stimulus in human adults with irritable bowel syndrome (IBS). The strain is also&#xD;
      considered safe and has previously been administered to pregnant and lactating women as well&#xD;
      as infants. Therefore, the study aims to evaluate the effect of probiotic (BL) NCC3001 on&#xD;
      mood and stress levels during the perinatal period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 6, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Individually unique coding for each stickpack</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EPDS score</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Measure change in trend of Edinburgh Postnatal Depression Scale (EPDS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in STAI score</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Measure change in trend of State Trait Anxiety Inventory (STAI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of EPDS score ≥ 13</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Number of subjects reaching Edinburgh Postnatal Depression Scale (EPDS) ≥ 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary Cortisol</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Measure change in the salivary cortisol levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenting stress</measure>
    <time_frame>12 weeks post-partum</time_frame>
    <description>Measured by the Parenting Stress Index (PSI) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>36 weeks pre-partum and 12 weeks post-partum</time_frame>
    <description>Measured by the Pittsburgh sleep quality index (PSQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition of stool</measure>
    <time_frame>Baseline to 12 weeks post-partum</time_frame>
    <description>Measure changes in the microbiota composition and probiotic strain colonization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal comfort</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Measure changes in Gastrointestinal symptom rating score (GSRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding practices</measure>
    <time_frame>Baseline and post-partum (9 days, 4 weeks, 8 weeks and 12 weeks)</time_frame>
    <description>Measure changes in Early Feeding Questionnaire (EFQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depressive symptoms</measure>
    <time_frame>Baseline and at 12 weeks post-partum</time_frame>
    <description>Measured by change in Hospital anxiety and depression scale (HADs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital assessments of stress</measure>
    <time_frame>Throughout the entire study</time_frame>
    <description>Change in stress index measured using ANURA application</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Perinatal Problems</condition>
  <condition>Mood Change</condition>
  <condition>Stress-related Problem</condition>
  <arm_group>
    <arm_group_label>Pre-Partum and Post-Partum (BL) NCC3001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily over a period of 6 months; 3 months pre- and post-partum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Partum (BL) NCC3001 (Crossover Arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Placebo stickpack containing maltodextrin, dissolved and consumed oral daily for 3 months during pre-partum, followed with switch to one stickpack containing probiotic strain (BL) NCC3001, dissolved and consumed oral daily for 3 months post-partum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>(BL) NCC3001</intervention_name>
    <description>Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.</description>
    <arm_group_label>Post-Partum (BL) NCC3001 (Crossover Arm)</arm_group_label>
    <arm_group_label>Pre-Partum and Post-Partum (BL) NCC3001</arm_group_label>
    <other_name>Bifidobacterium longum (BL) NCC3001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_label>Post-Partum (BL) NCC3001 (Crossover Arm)</arm_group_label>
    <other_name>Maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women aged 21 years-old or above at recruitment&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Gestational age of 28-32 weeks at Randomization&#xD;
&#xD;
          -  Singleton pregnancy at Recruitment&#xD;
&#xD;
          -  Able to respond to questionnaires in English&#xD;
&#xD;
          -  Hospital Anxiety and Depressive Scale (HADS) score of ≥ 5 (out of 21) for either&#xD;
             subscale to indicate some general feelings of low mood and/or stress at screening&#xD;
&#xD;
          -  Intention to breastfeed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing and/or not able to comply with the study procedures and requirements&#xD;
&#xD;
          -  Food allergy&#xD;
&#xD;
          -  Has taken probiotic supplements in the period of 4 weeks prior to screening&#xD;
&#xD;
          -  Has received pharmacological treatment for anxiety and/or depression in the period of&#xD;
             12 weeks prior to recruitment&#xD;
&#xD;
          -  Major complications during pregnancy e.g., pre-eclampsia, gestational diabetes&#xD;
             requiring insulin intervention, severe intra-uterine growth restriction (IUGR), fetal&#xD;
             anomalies that in the opinion of the investigator may interfere with the pregnancy and&#xD;
             participation in the clinical trial&#xD;
&#xD;
          -  Pre-existing medical conditions e.g., hypertension, diabetes mellitus, thyroid&#xD;
             diseases, autoimmune diseases such as Systemic Lupus Erythematosus, antiphospholipid&#xD;
             syndrome and other major chronic illness that in the opinion of the investigator may&#xD;
             interfere with the pregnancy and participation in the clinical trial&#xD;
&#xD;
          -  Active participation in another clinical trial or on-going observational study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Fries, PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>NESTLE RESEARCH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore Institute for Clinical Sciences, A*STAR Research Entities</name>
      <address>
        <city>Singapore</city>
        <zip>117609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>mood</keyword>
  <keyword>stress</keyword>
  <keyword>perinatal</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

